Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMLX Amylyx Pharmaceuticals

Post-Mkt 12-22 18:41:28 EST

12.50

+0.48

+3.99%

盘后12.54

+0.04+0.33%

18:22 EST

High12.60	Low11.92	Vol1.60M
Open12.20	D1 Closing12.02	Amplitude5.66%
Mkt Cap1.37B	Tradable Cap818.12M	Total Shares109.82M
T/O19.70M	T/O Rate2.44%	Tradable Shares65.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AMLX","market":"US","secType":"STK","nameCN":"Amylyx Pharmaceuticals","latestPrice":12.5,"timestamp":1766437200000,"preClose":12.02,"halted":0,"volume":1596504,"hourTrading":{"tag":"盘后","latestPrice":12.541,"preClose":12.5,"latestTime":"18:22 EST","volume":46631,"amount":582888.619144,"timestamp":1766445754538},"delay":0,"floatShares":65449399,"shares":109819569,"eps":-1.774191,"marketStatus":"Post-Mkt","change":0.48,"latestTime":"12-22 18:41:28 EST","open":12.2,"high":12.6,"low":11.92,"amount":19703150.34324,"amplitude":0.056572,"askPrice":13.44,"askSize":40,"bidPrice":11.71,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-1.774191,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1641531600000,"exchange":"NASDAQ","adjPreClose":12.02,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":13.1561,"preClose":12.02,"latestTime":"09:27 EST","volume":292,"amount":3712.269292,"timestamp":1766413675356},"postHourTrading":{"tag":"盘后","latestPrice":12.541,"preClose":12.5,"latestTime":"18:22 EST","volume":46631,"amount":582888.619144,"timestamp":1766445754538},"volumeRatio":0.666787,"impliedVol":0.5812,"impliedVolPercentile":0.452},"requestUrl":"/m/hq/s/AMLX","defaultTab":"news","newsList":[{"id":"2590376183","title":"Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590376183","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590376183?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:15","pubTimestamp":1765314907,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals (AMLX) has quietly staged a sharp rebound this year, with the stock up roughly 250% year to date and about 180% over the past year, drawing fresh attention from biotech investors.\nSee our latest analysis for Amylyx Pharmaceuticals.\nThe recent pullback, with a 1 day share price return of minus 3.7 percent and a 7 day share price return of minus 4.0 percent, looks more like a pause in what has been strong upward momentum, given the 30 day share price return of 11.1...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-amylyx-pharmaceuticals-amlx-overvalued-after-its-250-year","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-amylyx-pharmaceuticals-amlx-overvalued-after-its-250-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2589781231","title":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589781231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589781231?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:14","pubTimestamp":1764962096,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companiesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","COO","EQT","EXE","EUDA","FCX","INTS","LUV","BMEA","CHPT","TRMB","TTAN","WBD","ALB","DBRG","LU0320765646.SGD","CDE","PSN","FSLY","PKG","PRAX","FANG","XOM","RBRK","AUB","LU0128525689.USD","TE","ZUMZ","LU0128525929.USD","TARA","HL","AES","OMC","HPE","IOT","HUM","ITT","S","SCCO","DELL","ROL","LU1150488218.USD","ULTA","VSCO"],"gpt_icon":1},{"id":"2589818089","title":"BUZZ-Amylyx rises after promising early-stage trial for ALS drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818089","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818089?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:21","pubTimestamp":1764944492,"startTime":"0","endTime":"0","summary":"BUZZ-Amylyx rises after promising early-stage trial for ALS drug** Shares of drugmaker Amylyx Pharmaceuticals AMLX.O rise 1.8% to $14.75 premarket** Co says experimental drug, AMX0114, was generally well-tolerated by first group of patients in early-stage trial for amyotrophic lateral sclerosis, or ALS** ALS is a fatal condition that causes progressive muscle weakness and loss of movement, says co** Early-stage trial enrolled 12 patients, with no serious side effects linked to treatment - AMLX** Drug is injected into spinal fluid every four weeks; aims to protect nerve cells, co says** Second group enrollment to start in Canada this month and in January in the U.S. - AMLX** As of last close, stock up ~283% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL4N3XB145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2589818522","title":"BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818522","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818522?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:01","pubTimestamp":1764943311,"startTime":"0","endTime":"0","summary":"BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114 Dec 5 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:AMYLYX PHARMACEUTICALS ANNOUNCES NEW SAFETY AND TOLERABI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA3HTJKX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2589818532","title":"Amylyx Reports Positive Early Safety Data for AMX0114 in ALS Phase 1 LUMINA Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818532","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818532?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943245,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Inc. announced early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114, an investigational antisense oligonucleotide targeting calpain-2, in people with amyotrophic lateral sclerosis . The data from the first cohort  were presented at the 36th International Symposium on ALS/MND held December 5-7, 2025, in San Diego, California. According to the company, AMX0114 was generally well-tolerated, with no treatment-related serious adverse events reported. Based on these findings, enrollment for the second cohort is expected to begin in Canada later this month and in the U.S. in January. Amylyx plans to present biomarker data from the first cohort in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL1Tbk9C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2589818591","title":"Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of Amx0114 in ALS From First-in-Human Lumina Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818591?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA3HTJKX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2589818516","title":"Amylyx Pharmaceuticals Inc - Amx0114 Well-Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2589818516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589818516?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA3HTJKX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2588024054","title":"Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588024054","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588024054?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:40","pubTimestamp":1764798027,"startTime":"0","endTime":"0","summary":"Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLbrrlfj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2584926436","title":"Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926436","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926436?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:52","pubTimestamp":1763571155,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Amylyx Pharmaceuticals Q3 operating income USD -36.027 million vs. IBES estimate USD -43.1 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202511:00:00.293 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2fmpBP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2583451154","title":"Is Amylyx (AMLX) Reshaping Its Investment Case With Improved Losses and Avexitide’s Path to Market?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583451154","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583451154?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:36","pubTimestamp":1763059000,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals recently reported third quarter 2025 results, revealing a reduction in net loss to US$34.39 million, down from US$72.7 million a year earlier, and provided updates on its clinical pipeline including adjusted timelines for the pivotal Phase III LUCIDITY trial.\nAn important development is the progress toward a potential commercial launch for avexitide in 2027, reflecting the company's forward-looking investment in market readiness despite near-term trial delays.\nWe'll...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-amylyx-amlx-reshaping-its-investment-case-with-improved-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-amylyx-amlx-reshaping-its-investment-case-with-improved-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"1195243245","title":"Stock Track | Amylyx Pharmaceuticals Soars Nearly 7% as Mizuho Boosts Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1195243245","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195243245?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:32","pubTimestamp":1762785172,"startTime":"0","endTime":"0","summary":"Shares of Amylyx Pharmaceuticals (AMLX) are surging in Monday's pre-market session, climbing 6.99% following a significant price target upgrade from Mizuho analysts. The biotechnology company, which...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AMLX"],"gpt_icon":0},{"id":"1128500495","title":"Stock Track | Amylyx Pharmaceuticals Soars 5.61% Pre-Market as Mizuho Raises Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1128500495","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128500495?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:10","pubTimestamp":1762780235,"startTime":"0","endTime":"0","summary":"Shares of Amylyx Pharmaceuticals (AMLX) surged 5.61% in pre-market trading on Monday, following a positive adjustment in its target price by Mizuho analysts. The biotech company, known for its focus...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AMLX"],"gpt_icon":0},{"id":"1194455936","title":"Stock Track | Amylyx Pharmaceuticals Surges 5.61% Pre-Market on Mizuho's Target Price Hike","url":"https://stock-news.laohu8.com/highlight/detail?id=1194455936","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194455936?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:10","pubTimestamp":1762780222,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals (AMLX) stock is soaring in pre-market trading on Monday, with shares up 5.61% following a positive analyst action. The biotechnology company, known for its focus on developing...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AMLX"],"gpt_icon":0},{"id":"2582864200","title":"Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2582864200","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582864200?lang=en_us&edition=fundamental","pubTime":"2025-11-09 05:33","pubTimestamp":1762637622,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals (AMLX) stock has caught some attention recently, following several weeks of shifting trading patterns. Investors are keeping a close eye on the company as it navigates what has been a volatile stretch for biotech shares.\nSee our latest analysis for Amylyx Pharmaceuticals.\nDespite a few turbulent days, Amylyx Pharmaceuticals' momentum over the past year has been impressive, with a 61% share price return in the last 90 days and a 214.8% year-to-date gain. Although the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/assessing-amylyx-pharmaceuticals-amlx-valuation-following-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/assessing-amylyx-pharmaceuticals-amlx-valuation-following-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2581836447","title":"Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2581836447","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581836447?lang=en_us&edition=fundamental","pubTime":"2025-11-08 04:02","pubTimestamp":1762545720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 15:02 ET (20:02 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2581451888","title":"Amylyx Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $20 From $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2581451888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581451888?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:00","pubTimestamp":1762520443,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nAZN4QLSFO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2581013344","title":"Should Amylyx Pharmaceuticals' Sharply Reduced Net Losses Prompt a Rethink by AMLX Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2581013344","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581013344?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:48","pubTimestamp":1762447697,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals announced third quarter 2025 results, reporting a net loss of US$34.39 million and a loss per share of US$0.37, both improved from the previous year's figures for the same period.\nThe company's reduced losses over the last nine months highlight substantial changes in its cost structure or operational efficiency.\nWe'll look at how the marked decrease in net loss shapes Amylyx Pharmaceuticals' investment narrative going forward.\nRare earth metals are the new gold rush...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/should-amylyx-pharmaceuticals-sharply-reduced-net-losses-pro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/should-amylyx-pharmaceuticals-sharply-reduced-net-losses-pro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AMLX","ISBC","BK4007","BK4211"],"gpt_icon":0},{"id":"2581006725","title":"Amylyx Pharma Q3 loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2581006725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581006725?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:20","pubTimestamp":1762431601,"startTime":"0","endTime":"0","summary":"Amylyx Pharma Q3 loss narrowsOverviewAmylyx Q3 net loss narrows, beating analyst expectations for EPS and net incomeCompany's cash position strengthened by $191 mln public offering, extending runway i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2581062915","title":"Amylyx Pharmaceuticals Reports Third Quarter 2025 Results and Extends Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2581062915","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581062915?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:03","pubTimestamp":1762430588,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Inc. announced its financial and business results for the third quarter ended September 30, 2025. The company reported the completion of an underwritten public offering, resulting in net proceeds of approximately $191 million. This extends Amylyx's expected cash runway into 2028, covering the anticipated commercial launch of avexitide in 2027, pending approval. The company also stated that recruitment for the pivotal Phase 3 LUCIDITY trial of avexitide is expected to be completed in the first quarter of 2026, with topline data anticipated in the third quarter of 2026. Management will host a conference call and webcast to discuss these updates.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1GQ8X7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2581062540","title":"BRIEF-Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2581062540","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581062540?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430448,"startTime":"0","endTime":"0","summary":"Nov 06  - Amylyx Pharmaceuticals Q3 operating income USD -36.027 million vs. IBES estimate USD -43.1 million.Q3 net income USD -34.386 million vs. IBES estimate USD -41.6 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX498AA2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amylyx.com","stockEarnings":[{"period":"1week","weight":-0.0824},{"period":"1month","weight":-0.1606},{"period":"3month","weight":-0.0969},{"period":"6month","weight":1.3802},{"period":"1year","weight":2.0354},{"period":"ytd","weight":2.1799}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.037729},{"month":2,"riseRate":0.5,"avgChangeRate":0.096144},{"month":3,"riseRate":0.25,"avgChangeRate":-0.384218},{"month":4,"riseRate":0.25,"avgChangeRate":-0.062706},{"month":5,"riseRate":0.25,"avgChangeRate":-0.046188},{"month":6,"riseRate":0.75,"avgChangeRate":0.347356},{"month":7,"riseRate":1,"avgChangeRate":0.206362},{"month":8,"riseRate":0.5,"avgChangeRate":0.025088},{"month":9,"riseRate":0.75,"avgChangeRate":0.218209},{"month":10,"riseRate":0.75,"avgChangeRate":0.212399},{"month":11,"riseRate":0.75,"avgChangeRate":0.011294},{"month":12,"riseRate":0.25,"avgChangeRate":-0.128187}],"exchange":"NASDAQ","name":"Amylyx Pharmaceuticals","nameEN":"Amylyx Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amylyx Pharmaceuticals,AMLX,Amylyx Pharmaceuticals股票,Amylyx Pharmaceuticals股票老虎,Amylyx Pharmaceuticals股票老虎国际,Amylyx Pharmaceuticals行情,Amylyx Pharmaceuticals股票行情,Amylyx Pharmaceuticals股价,Amylyx Pharmaceuticals股市,Amylyx Pharmaceuticals股票价格,Amylyx Pharmaceuticals股票交易,Amylyx Pharmaceuticals股票购买,Amylyx Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction